17. July 2018
In May 2018 IPEC-Americas acquired ExcipientFest Americas and re-branded it "Excipient World". According to the organizers "Excipient World will continue the tradition of producing high quality education for all pharmaceutical professionals interested on the business, science, quality and safe use of excipients, as well as presenting a marketplace to connect buyers with industry suppliers to fuel global sales of excipients and new product innovations for years to come." The next event takes...
19. January 2018
The International Pharmaceutical Excipients Council (IPEC) is the global association of manufacturers and users of pharmaceutical Excipients. Each year, ExcipientFest Americas brings together a global community of Pharmaceutical Scientists for a unique two-day forum focused on the latest scientific research and developments for pharmaceutical excipients.
17. August 2017
The work on the educational program for 2018 has started. Do you have any excipient related topics you would like to hear about next year in Puerto Rico? Your suggestions are very welcome!
31. March 2017
ABSTRACT: CTwo year look back at the status of the NSF / IPEC / ANSI 363 GMP Standard for Pharmaceutical Excipients. What are we seeing as a certification body including best practices around risk assessment, quality improvement, the role of management and feedback from companies that have worked to meet the requirements of this GMP standard? More Information & Registration
23. March 2017
ABSTRACT: he current political environment, social climate, and economic challenges are creating enormous pricing pressures on the finished drug products marketed by the pharmaceutical industry regardless of branded formulation or a generic product. These extraordinary pricing pressures are applying greater pressure on the profitability of finished drug products. The need to maintain the profitability of the finished drug product is in turn driving the purchasing or sourcing strategy for lower...
10. March 2017
ABSTRACT: The presence of undetected impurities in drug products can lead to devastating side effects. For example, Diethylene Glycol (DEG) as an impurity has troubled the drug product industry for nearly 75 years. DEG has been used as a low cost but toxic substitute for glycerin and has directly caused the death of hundreds of children and adults. Tragedies such as these are preventable. The scope of this presentation is to discuss a scientific, collaborative and unbiased approach to the...
10. March 2017
ABSTRACT: Medical Marijuana products can be one of most promising therapeutics in the near future. However, its pharmaceutical use poses many formulation challenges: absortion, dosage variability, strain differences, extraction methods makes it potentially unpredictable. The purest and more effective forms of THC (99.9%) are highly unstable due to oxidation on room air, AXIM Biotechnologies patented a micro-encapsulation technology using gum base that preserves its integrity while ensuring drug...
10. March 2017
ABSTRACT: The operator of a filmcoating process typically has no control over the properties of tablet core and filmcoating material. Thorough understanding of the flmcoating process is therefore essential for the quality of the final, coated product. This presentation will map out the variables in the coating process and show their interdependence. Guidance will be given for a rational set up of coating processes. More Information & Registration
09. March 2017
ABSTRACT: Two year look back at the status of the NSF / IPEC / ANSI 363 GMP Standard for Pharmaceutical Excipients. What are we seeing as a certification body including best practices around risk assessment, quality improvement, the role of management and feedback from companies that have worked to meet the requirements of this GMP standard? More Information & Registration
09. March 2017
ABSTRACT: Counterfeit drugs pose a significant and fast-growing threat to public health and safety. The incident of counterfeit Avastin® in the United States demonstrates the vulnerability of the supply chain even in developed countries. Government health agencies and pharmaceutical manufacturers are finding ways to fight counterfeit and substandard drugs by identifying them from manufacturing, throughout the supply chain, and eventually when they reach the public in the retail pharmacies. In...